中国经前皮冠状动脉介入治疗ci指南9.pptVIP

DM Non-DM 5% 10% 6.2% Placebo GPIIb/IIIa Inhibitor 4.6% P=0.007 3.0% 3.0% P=NS GPIIb/IIIa Inhibitors in ACS 30-Day mortality results of a Meta-analysis* Circulation 2001;104:2767-71 * PRISM, PRISM-PLUS, PARAGON A B, PURSUIT, GUSTO-IV n= 6,458 n= 23,072 PCI No PCI 5% 10% 4.0% Placebo GPIIb/IIIa Inhibitor 1.2% P=0.002 6.7% 5.5% P=0.1 GPIIb/IIIa Inhibitors in Diabetic Patients with ACS Circulation 2001;104:2767-2771 30-Day Mortalityof a Meta-analysis* n= 1,279 n= 5,179 * PRISM, PRISM-PLUS, PARAGON A B, PURSUIT, GUSTO-IV Benefits of GP IIb/IIIa Inhibitors by Troponin Status in Clinical Tria